{'fraction_non_alphanumeric': 0.030603804797353185, 'fraction_numerical': 0.013234077750206782, 'mean_word_length': 4.902439024390244, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The effect of carboplatin combined chemotherapy on renal function in patients with ovarian carcinoma].

OBJECTIVE
To investigate the changes of renal function during carboplatin (CBDCA) combined chemotherapy in patients with ovarian carcinoma.


METHODS
26 courses of postoperative systemic CBDCA therapy were carried out in 7 patients with ovarian carcinoma. During chemotherapy both systolic maximum and diastolic minimum blood flow velocity (Vmax, Vmin) and resistance index (RI) in renal segmental artery (SA) and interlobular artery (ILA) were meaured by color doppler weekly. Meanwhile renal creatinine clearance rate (Ccr) were also determined. 14 healthy women were taken as controls.


RESULTS
From the 1st week to the 3rd week at the begining of CBDCA therapy, Vmax and Vmin in SA and ILA were significantly decreased (P < 0.01). A significant positive correlation was found between Ccr and the values of Vmin in SA and ILA (r = 0.52, P < 0.01).


CONCLUSIONS
The results indicated that carboplatin combined chemotherapy could induce disturbances of renal function. The changes of renal function were related to renal blood flow velocity which could be used as a monitoring index of renal function.